First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence
Author Information
Author(s): J Sandercock, MKB Parmar, V Torri
Primary Institution: MRC Cancer Trials Office
Conclusion
Cisplatin combined with paclitaxel is more effective than cisplatin combined with cyclophosphamide, although one trial suggests single-agent cisplatin may be equally effective.
Supporting Evidence
- Cisplatin combined with paclitaxel shows improved overall survival compared to cyclophosphamide.
- One trial suggests that a higher dose of single-agent cisplatin may be as effective as the combination treatment.
- Statistical tests indicate significant differences in survival outcomes between treatment groups.
Takeaway
Doctors are trying to find the best way to treat advanced ovarian cancer, and they think a mix of two medicines, paclitaxel and cisplatin, works better than one medicine alone.
Methodology
Four randomized trials were compared, focusing on the effectiveness of paclitaxel and cisplatin versus other treatments.
Potential Biases
Potential false-positive and false-negative results in trials could affect the conclusions.
Limitations
The results of one trial were not available, and there was considerable statistical and clinical heterogeneity among the trials.
Participant Demographics
Patients with advanced ovarian cancer, specifically FIGO stage IIIB or IV.
Statistical Information
P-Value
0.00041
Confidence Interval
(0.53-0.83)
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website